The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. North America accounted for the largest share of the market. Factors such as the rising prevalence of chronic diseases, increasing healthcare expenditure, the high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the market in North America.
Request for Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145
Emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.
Key Market Players
The global anatomic pathology market for instruments and consumables is consolidated. The top five companies in this market are F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Beckton, Dickson and Company (US), and Abcam plc. (UK).
- Hoffmann-La Roche AG (Switzerland) was the leading player in the anatomic pathology market. The company has a wide range of products in the consumables segment. Strong business operations across all key regions, coupled with a strong brand image, make the firm a leading player in this market. F. Hoffman-La Roche has adopted organic business strategies such as product launches in order to maintain its leading position in the anatomic pathology market.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145
Danaher Corporation (US) was the second-leading player in the anatomic pathology market in 2020. The company has a broad product portfolio in the instruments segment. Moreover, Danaher also has a strong geographic presence with its direct distribution channels across the globe. The impressive product portfolio of the firm is complemented by its client support services.
Recent Developments:
- In May 2021, Hologic received premarket approval (PMA) from the FDA for its ThinPrep GenesisTM processor for cytology processing and specimen transfer for downstream applications.
- PHC Holding Corporation completed the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business to strengthen its position in the diagnostics segment.
Request for Custom Research @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=137323145
